Literature DB >> 15301872

Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma.

A Bajard1, V Westeel, A Dubiez, P Jacoulet, D Pernet, J C Dalphin, A Depierre.   

Abstract

Brain metastases are a frequent feature of the course of non-small cell lung carcinoma (NSCLC). The potential usefulness of prophylactic cranial irradiation (PCI) has led to the search for target groups likely to derive benefit. This multivariate analysis looked for factors predictive of brain metastases in a group of stages I-III NSCLC patients under care of the thoracic oncology unit of Besançon University Hospital from 1977 to 2001. All the patients had the same follow-up. They were divided into two groups: BM+ when they had a brain metastasis as the first site of progression, whether solitary or not, and BM(-) otherwise. Variables analysed were age, gender, performance status (0-1 versus 2-3), weight-loss stage T-status, N-status, pathological type, type of treatment, administration of chemotherapy, use of cisplatin and response to treatment. Three hundred and five patients were eligible and there were 77 patients (25.25%) in the BM+ group. Median time to onset of brain metastases was 12 months (1-163 months) and median survival from the diagnosis of brain metastases was 6 months (1-65 months). Factors predictive of brain progression were age < or =62 years (RR: 2.5, 95% CI: 1.33-4.76 and P = 0.004), T4 tumour status (RR: 3.75, 95% CI: 1.72-8.21 and P = 0.0009), N2-3 (RR: 2.61, 95% CI: 1.32-5.15 and P = 0.0057), and adenocarcinoma (RR: 3.39, 95% CI: 1.78-6.46 and P = 0.0002). No aspect of treatment plays a role in the frequency of this type of metastasis. These factors predictive of brain progression could serve as a basis for the selection of patients with the aim of sitting of studies on prophylactic cranial irradiation in NSCLC.

Entities:  

Mesh:

Year:  2004        PMID: 15301872     DOI: 10.1016/j.lungcan.2004.01.025

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  32 in total

1.  Incidence of brain metastasis in patients with esophageal carcinoma.

Authors:  Ron S Smith; Robert C Miller
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

2.  [Quality of life after prophylactic cranial irradiation in locally advanced non-small-cell lung cancer].

Authors:  F Oskan; D Vordermark
Journal:  Strahlenther Onkol       Date:  2012-04       Impact factor: 3.621

3.  HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report.

Authors:  Jiaxin Niu; Deborah Gelbspan; David Weitz; Maurie Markman; Walter Quan
Journal:  J Gastrointest Oncol       Date:  2014-12

Review 4.  Potential toxicities of prophylactic cranial irradiation.

Authors:  Frank A Giordano; Grit Welzel; Yasser Abo-Madyan; Frederik Wenz
Journal:  Transl Lung Cancer Res       Date:  2012-12

5.  What Factors Are Associated With Local Metastatic Lesion Progression After Intramedullary Nail Stabilization?

Authors:  Punthitra Arpornsuksant; Carol D Morris; Jonathan A Forsberg; Adam S Levin
Journal:  Clin Orthop Relat Res       Date:  2021-12-28       Impact factor: 4.176

6.  Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial.

Authors:  Xiao-Xiao Dinglin; Yan Huang; Hui Liu; Yin-Duo Zeng; Xue Hou; Li-Kun Chen
Journal:  J Neurooncol       Date:  2013-02-19       Impact factor: 4.130

Review 7.  Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.

Authors:  Rimas V Lukas; Maciej S Lesniak; Ravi Salgia
Journal:  CNS Oncol       Date:  2014-01

Review 8.  Prophylactic cranial irradiation: recent outcomes and innovations.

Authors:  James W Snider; Vinai Gondi; Paul D Brown; Wolfgang Tome; Minesh P Mehta
Journal:  CNS Oncol       Date:  2014-05

9.  Incidence and patterns of isolated brain failure in stage III non-small-cell lung cancer treated with concurrent chemoradiation therapy.

Authors:  Yasushi Hamamoto; Masaaki Kataoka; Takatoshi Senba; Kotaro Uwatsu; Shogo Oda; Tadaaki Takahashi; Shoji Aono; Shinya Sakai; Takeshi Inoue; Yoshifumi Sugawara
Journal:  Jpn J Radiol       Date:  2009-02-08       Impact factor: 2.374

10.  Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer.

Authors:  Xiao Ding; Honghai Dai; Zhouguang Hui; Wei Ji; Jun Liang; Jima Lv; Zongmei Zhou; Weibo Yin; Jie He; Luhua Wang
Journal:  Radiat Oncol       Date:  2012-07-30       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.